ABOUT

CANNABICS
PHARMACEUTICALS

CANNABICS
PHARMACEUTICALS

Cannabics Pharmaceuticals has been conducting research on the antitumor effects of cannabinoid formulations on cancer since its establishment in 2012.

  • Founded 2012
  • Capital Markets: OTCQB (CNBX)
  • Capital raised to date: 12M usd
  • Licensed by the Israeli Ministry of Health to conduct research using cannabinoids on cancer
  • State of the art in-house drug discovery facilities

MANAGEMENT

EYAL BARAD Co-Founder, Director, CEO Mr. Barad holds a BA in Economics & International Relations from the Hebrew University in Jerusalem and an MBA with Honors from Haifa University.
Prior to becoming CEO at Cannabics, Mr. Barad served as Vice President of the Israel Canada Chamber of Commerce, and as CEO of an international digital media company.
GABRIEL YARIV President, Director, COO Mr. Yariv holds a BA Cum Laude from Boston University in Philosophy, Political Science and History.
Mr. Yariv brings over 20 years of successful executive experience in the medical industry. Mr. Yariv was part of the funding group of breathID an Oridian medical (now Medtronic) business unit and its subsequent spin off company breath ID Inc. (now Exalenz bio science) which develops and manufactures advanced non-invasive diagnostic medical devices for gastrointestinal and liver conditions. Mr. Yariv also co-founded Simutec, a medical simulation and training company in Brazil that develops and commercializes advanced personalized virtual reality training programs for physicians,
DR. EYAL BALLAN Co- Founder, CTO Holds a Ph.D. In Neurophysiology, Brain Waves and Cortical Connectivity.
After obtaining his Ph.D. He was an entrepreneur in the field of Neurofeedback. Dr. Ballan holds an MSC from Tel-Aviv University Magna Cum Laude in Molecular Biology and Anticancer Drug Development.
URI BEN-OR CFO Has over 20 years of broad experience in corporate finance, accounting, M&A transactions, IPO’s and operations.
Mr. Ben-or is CEO & founder of one of the few financial firms in Israel to have the international standard on assurance engagement (ISAE 3402/SAS 70 type ii) assurance with control compliances, the new global standard for assurance reporting. He previously served as an auditor at Price Waterhouse Coopers (PWC) accounting firm. Mr. Ben-Or holds a BA in Business from the College of Administration and an MBA from the Bar-Ilan University and is a Certified Public Accountant (CPA).
DR. ILAN HOCHMAN VP of R&D Dr. Hochman holds a PhD in cancer Immunology.
He brings more than 20 years of experience in versatile R&D leadership and management positions in Innovative biotechnology and startup companies. Before joining Cannabics, Dr. Hochman was a co-founder and VP of R&D at SURI Technologies, a company focusing on developing personalized cancer immunotherapy. Previously he was the founder of Biology Research Services, a company that provided Tailor-made solutions for startups research, and managed the bioassay and HTS units at QBI and Rosetta Genomics.
DR. LIOR ESHDAT IP Manager Dr. Eshdat holds a Ph.D. in organic chemistry and brings over 13 years of experience in intellectual property practice.
Before he became an Israeli Patent Attorney he held a post-doctoral research fellowship at the University of Boulder and was a senior chemist in Dynamic Organic Light which developed OLED display technologies in Colorado.
Dr. Eshdat gained his IP experience as a patent attorney associate in Reinhold Cohn, a leading Israeli IP Firm, in the in-house IP departments in Adama, a global agchem corporate, and through his own practice providing IP consultancy and patent attorney services to inventors, start-ups, entrepreneurs and hedge funds.
DAVID E. PRICE ESQ Took the company public on the US capital market and is a native Washingtonian.
David brings a dynamic and varied background, having worked in the Diplomatic Corps in the Israeli Foreign Office as well as a Congressional Aide in the US congress, and General Counsel to consultants at the World Bank as well as the IDB, ex-im and IMF in Washington, DC.

ADVISORY BOARD

DR. GIL FEILER Head Of Advisory Board Former board member of Advanced Vision Technology (FTX: VSJ), board of Safra bank mutual fund division, administrative advisor for the government of Ras Al Khaimah, UAE.
Author of numerous publications, a known speaker at leading business events including Davos world economic forum.
PROF. ZAMIR HALPERN Medical Advisor Prof. Halpern, Senior Physician at the Gastroenterology institute in the Sourasky Medical Center in Tel-Aviv, Israel, served as Chairman of the Israeli Association of the Study of Liver, Chairman of the Israeli Gastroenterology Association, Chairman of the National Council for Food and Agriculture and is now Chairman of the National Gastro Nutrition and Liver Diseases Council at the Ministry of Health.
DR. EREZ SCAPA Medical Advisor Dr. Scapa earned his M.D in 2000 at the Technion Institute of Technology in Haifa, Israel, cum laude. He later held a Research Fellowship in Hepatology at the Brigham and Women’s Hospital, Harvard University, Boston, MA, as well as a fellowship in Endoscopic Submucosal Dissection at the NTT Medical Center in Tokyo, Japan. He is an expert in invasive Endoscopy and has extensive experience in performing colonoscopies and gastroscopies. He is proficient in both diagnostic as well as invasive Endoscopic US (EUS) and serves as the head of the Endoscopic Submucosal Dissection (ESD) program in Tel-Aviv Sourasky Medical Center, initiated in 2019.
PROF. AMOS TOREN, MD Medical Advisor Prof. Amos Toren is the Director of Pediatric Hemato- Oncology and BMT department at the Sheba Medical Center since 2001 and a Professor in the division of Hematology,Sackler school of medicine tel-aviv university.
Prof. Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-oncology. He also has a Ph.D degree in genetics and qualified as a master of health administration (MHA) at the Recannati Business School, Tel-Aviv University.
DR. TAL MOFKADI Financial Advisor Dr. Mofkadi holds a Ph.D in Financial Economics from Tel Aviv University. He is a lecturer at Tel Aviv University, the Interdisciplinary Center in Herzliya and universities abroad.
He is the author of ‘The Handbook of Corporate Valuation’.
Dr. Mofkadi provides expert opinions in financing, economic, and legal proceedings, writing valuations and optimal pricing policies as well as economic analysis of competition and regulatory aspects, risk assessment and more.
DR. SIGALIT ARIELY PORTNOY Regulatory Advisor Dr. Sigalit Ariely-Portnoy has vast experience in the pharmaceutical industry and managed pharmaceutical and chemical plants at Taro Pharmaceutical Industries LTD as Operation Group Vice President and in Teva Pharmaceutical industries LTD as OSD plant manager.
In the last 7 years, Sigalit is the CEO of GSAP, the largest consulting company for pharmaceutical and medical device companies in Israel.
Sigalit Ariely-Portnoy has a BSC and Ph.D in Chemical Engineering and MSC in Bio-Medical engineering from the Technion – Israel Institute of Technology, Haifa, Israel. regulatory aspects, risk assessment and more.
DR. DANA BEN-AMI SHOR Medical Advisor Dr. Ben-Ami Shor is a recognized expert in invasive endoscopy and gastroenterology in the Sourasky Medical Center in Tel-Aviv, Israel.
Dr. Ben-Ami Shor earned her M.D in 2009, graduating cum laude from the Sackler Faculty of Medicine, Tel Aviv University. She specialized in internal medicine and gastroenterology at the Sheba Medical Center, Israel. She also successfully completed an advanced endoscopy (ASGE) accredited fellowship within the Center for Interventional Endoscopy at AdventHealth, in Florida.
Additionally, Dr. Ben-Ami Shor is proficient in both diagnostic and therapeutic endoscopic ultrasound (EUS), and endoscopic retrograde cholangiopancreatography (ERCP).